SUMMARY A double blind crossover trial of 20 [tg intranasal 1-deamino-8-D-arginine vasopressin (DDAVP) versus placebo was carried out in 17 children with intractable enuresis aged between 6 and 13 years who had failed to respond to drugs and an enuresis alarm. Fluid intake was not restricted. There was a significant reduction in the number of wet nights. Seven children (41%) were cured or showed considerable improvement, with strong evidence against any placebo effect. The best response was seen in children aged 10 years or over and if urine osmolality after DDAVP reached beyond 1000 mmol/kg or was already at this concentration. The degree of overnight rise in urine osmolality after treatment with DDAVP was not predictable but correlated well with the clinical improvement in nocturnal diuresis present in eight of the children.
Intranasal 1-deamino-8-D-arginine vasopressin (DDAVP), the synthetic analogue of vasopressin, is the treatment of choice for diabetes insipidus that is sensitive to vasopressin because it has a prolonged anti-diuretic action dependent on dose with no side effects' 2 nor inhibition of growth hormone, prolactin, or cortisol at night in children. 2 Could nocturnal enuresis be helped by this antidiuresis? In a pilot study 10 [tg of intranasal DDAVP was effective in 11 of 20 children with resistant enuresis.3 This was confirmed with ,ug both in controlled studies-6 and double blind clinical trials,7 12 with but one dissent.'3 But in many of these studies an enuresis alarm (the 'buzzer') had never been used and the degree of enuresis was not severe. In diabetes insipidus there is a consistent and considerable rise in urine osmolality after treatment with DDAVP, but there has been no such detailed study of this topic in enuresis. A double blind trial with crossover was therefore designed not only to determine the value of 20 ,ug DDAVP in enuresis refractory to conventional treatment, including the buzzer, but more importantly to see whether a rise in urine osmolality was a necessary factor in any success achieved. 
Results
Clinical. There were no side effects and there was no clinical evidence of overhydration and no significant change in blood pressure or body weight.
Overall, treatment with DDAVP produced a significant clinical improvement, with 117 wet nights in two weeks against 169 on placebo (p<0-02 by the Wilcoxon method for ranked paired data). Two children showed complete cure during the treatment with DDAVP (all nights dry), five were greatly improved (at least five dry nights a week), five were slightly improved (averaging three dry nights a week, one night more than with placebo), and five were failures, including three who became dry at the mother's bedtime and were less 'soaked' by morning. Thus treatment with DDAVP was successful in seven of the 17 children (41%). That these successes might have been due to a placebo effect was unlikely because there were no successes on placebo, only five improving slightly and the remainder being failures. Moreover, when the placebo was given first (10 cases) all but two (who failed clinically) of the children showed greater improvement when subsequently treated with DDAVP, whereas when the active drug was given first (seven cases) treatment with placebo showed greater improvement in only two (who were also failures).
No significant difference was found between children from intact and broken homes or between those who had and had not been wet every night. Older children, however, fared better than younger ones, with four successes in the six who were aged 10 years or more (56 dry nights in two weeks, mean 9-3) but only three in the 11 aged less than 10 (55 dry nights in two weeks, mean 5X9) (x2= 12-05, p<-001).
Urine osmolality. The range of overnight urine osmolality in normal children is 873-1305 mmoll kg.14 Osmolality was increased by treatment with DDAVP in all but five of the children. There was a clear and significant relation between osmolality and clinical response (Table 1) . The best results were achieved if overnight urine osmolality after treatment with DDAVP increased beyond 1000 mmollkg or if it was already at this concentration after treatment with placebo, which allowed little room for a further increase (four cases, comprising three successes and one failure). If urine osmolality failed to reach 1000 mmollkg, however, results with one exception were poor (p<0-005).
There were eight presumed cases of nocturnal water diuresis, who had an overnight urine osmolality of 250-505 mmollkg, in contrast to the remaining nine, whose range was 745-1143 mmol/kg ( Table 2) . Clinical results were good in three and four children from these two groups. respectively, but the five with nocturnal diuresis who gave poor results included two whose osmolalities were virtually unchanged after the drug from a base so low (310 and 325 mmol/kg, respectively, after placebo) that either DDAVP was not taken or not absorbed or else tubular function was so impaired by gross polydipsia as to render the drug useless. One of these two children was admitted to hospital for investigation and treatment with DDAVP; no abnormality was discovered and he was dry three nights out of four when receiving DDAVP so that it is probable that he was not taking it at home.
The most likely cause of nocturnal diuresis is compulsive drinking on the previous evening. This hypothesis is supported by the finding ( Table 2 ) that in all eight cases the osmolalities in the afternoon before the trial began averaged 131% higher than that recorded in the urine specimens taken the first morning after placebo; this compares with only 2-5% higher in the nine cases in whom nocturia was absent.
Subsequent experience It was found that those who responded to treatment with DDAVP did so very quickly but relapsed when it was stopped. Its appropriate use would therefore apply to urgent situations such as school journeys and holidays.3 During the three years since this trial was completed, therefore, 12 more children aged between 7 and 13 years with equally refractory enuresis have been given 20 [ig DDAVP to take on such occasions.
Before departure, overnight urine osmolalities were normal in six, but in the other six they were abnormally low (-651 mmol/kg). Success was achieved in seven of the 12 (58%), five with nocturnal diuresis but only two with normal osmolalities. Four of the five successes with nocturnal diuresis were so delighted that they asked for DDAVP again for the same purpose (one had it three times and two twice) with the same improvement on each occasion, even though they relapsed soon afterwards. It was not practicable to estimate urine osmolality immediately after their return, but it is suggested that any benefit obtained was due to anti-diuresis.
Discussion
This double blind crossover trial shows the efficacy and safety of treatment with 20 ,ug DDAVP even in patients with intractable nocturnal enuresis, all of whom had failed to respond to drugs and the buzzer. Considerable improvement was obtained in almost half of these children (41%), with substantial evidence against a placebo effect. This overall figure does not differentiate, however, between the children with and without nocturnal polyuria. This distinction is admittedly based on only three tests of urine osmolality on different days but it proved impracticable to do more in a busy clinic remote from the local laboratory. This limitation, however, should not invalidate the overall conclusions.
Eight of these 17 children probably had nocturnal diuresis, given their low overnight urine osmolality (<505 mmol/kg ) on placebo, which possibly correlated with compulsive drinking on the previous evening because of the significant difference between the fairly high urine osmolalities on the afternoon before the trial began and the low readings in the first morning urine samples after treatment with placebo. Naturally, in any individual the degree of compulsive polydipsia, presumably psychogenic, is impossible to quantify as it is so often surreptitious. But even without polydipsia, nocturnal concentrations of anti-diuretic hormone have been found to be fairly low in children with enuresist5 but sufficient to allow urinary output to exceed the functional capacity of the bladder. Unfortunately, DDAVP was not used in that study, but if low anti-diuretic hormone concentrations can be confirmed DDAVP might be regarded as replacement therapy.
Further study of the interaction between DDAVP, severe enuresis, nocturia, and compulsive polydipsia with larger numbers seems highly desirable.
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